| Yazarlar (3) |
Zaid Husham Al-Sawaff
|
|
Serap Şentürk Dalgıç
Türkiye |
Prof. Dr. Fatma KANDEMİRLİ
Kastamonu Üniversitesi, Türkiye |
| Özet |
| Osteoporosis is a disease characterized by low bone mass and the microarchitectural deterioration of bone tissue, leading to bone fragility and increased fracture risk [1]. Most of the therapies used for the treatment of osteoporosis inhibit bone resorption and prevent further bone loss. However, as many osteoporosis patients already lost a large amount of bone at their diagnosis, agents need agents to stimulate new bone formation [2].This approach’s drug and enhancements’ discovery goal is to identify a CaSR-antagonist, that is, rapidly absorbed (short Tmax) and fairly rapidly eliminated. Based on its overall in vitro and physicochemical properties, one of the BMSF-BENZ derivatives ((4-Bromo-7-methoxy-1-(2-methoxyethyl)-5-{[3-(methylsulfonyl) phenyl] methyl}-2-[4-(propane-2-yl) phenyl]-1H-1, 3-benzothiazole)(Figure 1) was selected because it showed a sharp PTH-release peak and good properties regarding CaSR receptor [3]. With the increasing development of |
| Anahtar Kelimeler |
| Makale Türü | Özgün Makale |
| Makale Alt Türü | Uluslararası alan indekslerindeki dergilerde yayınlanan tam makale |
| Dergi Adı | European Journal of Chemistry |
| Dergi ISSN | 2153-2249 |
| Dergi Tarandığı Indeksler | WorldCat, Index Copernicus |
| Makale Dili | Türkçe |
| Basım Tarihi | 01-2021 |
| Makale Linki | www.eurjchem.com |
